The common dosage forms are including oral, inhaled, topical, rectal and parenteral routes. Formulation screening is the process of selecting the best prescription through various techniques and analytical methods. The aim of formulation screening is making the drug formulation more safer, effective, reasonable, stable, convenience and economic. Selection of appropriate excipients, the best preparation process, and the best form of preparation can be used to facilitate the development and clinical study of the late preparations. Such as, appropriate type and dosage of excipients result in satisfactory release behavior from tablets or capsules, which is the most prerequisite for achieving an excellent treatment efficacy.
Physicochemical properties of excipients have a significant impact on the fabricating of pharmaceutic preparation. The advanced platforms and experts of the BOC science can offer customers with the high quality services of excipient screening by examination of the micromeritics, mechanical properties, and particle crystallinity. Micromeritics or powder characterization analysis is an effective method for prediction of the behavior of blending, compaction, stability, disillusion and bioavailability. Understanding of powder characteristics including the particles size distribution, particles shape, density and flow properties helps us to dictate how blends will behave during subsequent processing.
The drug excipient compatibility analysis provides a comprehensive understanding of the interaction between inactive ingredients or excipients and drugs, which offer the beneficial information and reference for the selection of excipients. Although excipients are usually pharmacologically inert, they may undergo physicochemical reactions with the drug compounds and even other kinds of excipients after being mixed with each other during the formulation development. Besides considering the physical incompatibility, chemical incompatibility, and therapeutic incompatibility, we also provide three types of compatibility analyses including Drug-excipient Compatibility Screening, Drug-drug Compatibility Screening, and Excipient-excipient Compatibility Screening.
The solubilization of poorly soluble drugs is a frequently encountered challenge in screening studies of new chemical entities as well as in formulation design and development. Orally administered drugs can only be completely absorbed when they show fair solubility in gastric medium and such drugs show good bioavailability. Bioavailability depends on several factors, drug solubilization in an aqueous environment and drug permeability through lipophillic membranes being the important ones.
One reason that surfactant is useful is that, under suitable conditions, their aqueous solutions are able to dissolve substantial amounts of compounds that have very low solubility in water. Similarly, the surfactant can greatly increase the solubility of water and other polar compounds in hydrocarbons and other liquids of low polarity. This phenomenon, which involves incorporation of the solute by aggregates of surfactant molecules, is known as solubilization.
Nanosuspensions are simple to prepare and have been developed as promising candidates for the effective delivery of hydrophobic drugs, typically for oral and topical use or parenteral and pulmonary administration. The nanosuspension not only solves the problem of poor solubility and bioavailability, but also changes the pharmacokinetics of the drug, thereby improving the safety and effectiveness of the drug. This method is useful for molecules with poor solubility, poor permeability, or both, posing a major challenge for formulators.
BOC Sciences’ experienced material scientists can support your formulation design and screening to allow selection of your excipients for preclinical evaluation and identification of your drug product in early clinical evaluation. Our rapid screening approach uses techniques such as particle size analysis, solubility screening, amorphous content and candidate stability to identify your lead candidates, which can then be developed into formulations for preclinical evaluation as either simple solutions/suspensions or more complex formulations. By rapidly screening excipients and selecting appropriate formulations, you can begin preclinical studies in a matter of weeks rather than months.